EGFR AND HER2: AN ONCOGENIC ALLIANCE

被引:0
|
作者
Yarden, Y. [1 ]
机构
[1] Weizmann Inst Sci, IL-76100 Rehovot, Israel
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:21 / 21
页数:1
相关论文
共 50 条
  • [41] New agents for targeting egfr/her2: where are we?
    Cheol, Chung Hyun
    9TH INTERNATIONAL GASTRIC CANCER CONGRESS (IGCC 2011): A GATE TO THE FUTURE OF GASTRIC CANCER TREATMENT, 2011, : 7 - 12
  • [42] Expression of EGFR and HER2 in pediatric enbryonal brain tumours
    Stefanaki, K.
    Patereli, A.
    Anagnostopoulou, Doussis, I
    Moschovi, M.
    Constantinidou, Van Vliet C.
    Karamolegou, K.
    Sfakianos, G.
    Prodromou, F.
    Karentzou, O.
    VIRCHOWS ARCHIV, 2009, 455 : 154 - 155
  • [43] Renal toxicity of anticancer agents targeting HER2 and EGFR
    Laura Cosmai
    Maurizio Gallieni
    Camillo Porta
    Journal of Nephrology, 2015, 28 : 647 - 657
  • [44] The immunoexpression of EGFR and Her2/neu in oral squamous carcinoma
    Dragomir, L. P.
    Margaritescu, Cl.
    Florescu, Alma
    Olimid, A. D.
    Dragomir, Manuela
    Popescu, M. R.
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2012, 53 (03): : 597 - 601
  • [45] Renal toxicity of anticancer agents targeting HER2 and EGFR
    Cosmai, Laura
    Gallieni, Maurizio
    Porta, Camillo
    JOURNAL OF NEPHROLOGY, 2015, 28 (06) : 647 - 657
  • [46] EGFR and HER2 expression in advanced biliary tract cancer
    Harder, Jan
    Waiz, Oliver
    Otto, Florian
    Geissler, Michael
    Olschewski, Manfred
    Weinhold, Brigitte
    Blum, Hubert E.
    Schmitt-Graeff, Annette
    Opitz, Oliver G.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (36) : 4511 - 4517
  • [48] A dual degrader of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models
    Yang, Lu
    Bhattacharya, Arup
    Peterson, Darrell
    Li, Yun
    Liu, Xiaozhuo
    Marangoni, Elisabetta
    Robila, Valentina
    Zhang, Yuesheng
    CANCER RESEARCH, 2024, 84 (06)
  • [49] Selective therapeutic antibodies against oncogenic mutations of HER2 ectodomain
    Bang, Injin
    Hattori, Takamitsu
    Leloup, Nadia
    Corrado, Alexis
    Nyamaa, Atekana
    Koide, Akiko
    Geles, Ken
    Buck, Elizabeth
    Koide, Shohei
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [50] Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain
    Bang, Injin
    Hattori, Takamitsu
    Leloup, Nadia
    Corrado, Alexis
    Nyamaa, Atekana
    Koide, Akiko
    Geles, Ken
    Buck, Elizabeth
    Koide, Shohei
    NATURE CHEMICAL BIOLOGY, 2024,